Page 1 | Search Results | Blood | American Society of Hematology

1-9 of 9

Sort by

Sort Order Select

Journal Articles

Antibiotic Overload: Antibiotic Stewardship in Febrile Patients with Hematologic Malignancies

Ricardo Parrondo, MD, Veronica Mariotti, MD, Camille Johnson, MD, Faiz Afridi, MD, Tracy Andrews, PhD, Lori A. Leslie, MD

Blood (2017) 130 (Supplement 1): 3402.

https://doi.org/10.1182/blood.V130.Suppl_1.3402.3402

Published: 2017

Journal Articles

Cyclophosphamide Based Regimens Compared to Plerixafor-Based Regimens for Stem Cell Mobilization in Patients with Multiple Myeloma Result in Higher CD34+ Cell Yield, Lower Cost and Similar Outcome Post Autologous Transplantation

Rima M Panchal, MD, Phyllis McKiernan, APN, MSN, David Siegel, MD PhD, Scott D. Rowley, MD, David H. Vesole, MD PhD, Tracy Andrews, PhD, Andrea Ortega, RN, Alan P Skarbnik, MD, Noa Biran, MD, Joshua R Richter, MD, Nino Aleksidze, MD, Andrew L. Pecora, MD, Andre Goy, MD, Maribel Pereiras, Pharm D, Michele L. Donato, MD

Blood (2017) 130 (Supplement 1): 3283.

https://doi.org/10.1182/blood.V130.Suppl_1.3283.3283

Published: 2017

Journal Articles

Risk of Engraftment Syndrome after Autologous Stem Cell Transplantation for Multiple Myeloma Increases with Age and Lower Dose of CD34+ Cells, but Is Not Impacted By Immunomodulatory Chemotherapy

Phyllis McKiernan, APN, MSN, David Siegel, MD PhD, Scott D. Rowley, MD, David H. Vesole, MD PhD, Tracy Andrews, PhD, Andrea Ortega, RN, Alan P Skarbnik, MD, Noa Biran, MD, Joshua R Richter, MD, Andrew L. Pecora, MD, Andre Goy, MD, Rima M Panchal, MD, Nino Aleksidze, MD, Michele L. Donato, MD

Blood (2017) 130 (Supplement 1): 3284.

https://doi.org/10.1182/blood.V130.Suppl_1.3284.3284

Published: 2017

Journal Articles

Outcomes of Autologous Stem Cell Transplantation in Very Elderly Patients with Multiple Myeloma

Phyllis McKiernan, APN, MSN, David Siegel, MD PhD, David H. Vesole, MD PhD, Scott D. Rowley, MD, Tracy Andrews, PhD, Andrea Ortega, RN, Alan P Skarbnik, MD, Noa Biran, MD, Joshua R Richter, MD, Andrew L. Pecora, MD, Andre Goy, MD, Rima M Panchal, MD, Nino Aleksidze, MD, Michele L. Donato, MD

Blood (2017) 130 (Supplement 1): 2013.

https://doi.org/10.1182/blood.V130.Suppl_1.2013.2013

Published: 2017

Journal Articles

Patients Responding to Any First Line Therapy for Multiple Myeloma Should Proceed to Autologous Stem Cell Transplantation Instead of Receiving Second Line Therapy to Deepen Response

Nino Aleksidze, MD, Phyllis McKiernan, APN, MSN, David Siegel, MD PhD, Scott D. Rowley, MD, David H. Vesole, MD PhD, Tracy Andrews, PhD, Andrea Ortega, RN, Alan P Skarbnik, MD, Noa Biran, MD, Joshua R Richter, MD, Andrew L. Pecora, MD, Andre Goy, MD, Rima M Panchal, MD, Michele L. Donato, MD

Blood (2017) 130 (Supplement 1): 4538.

https://doi.org/10.1182/blood.V130.Suppl_1.4538.4538

Published: 2017

Journal Articles

Treatment of High Risk DLBCL with DA-R-EPOCH in Those Unable to Tolerate Intensive Chemotherapy: Well-Tolerated and Effective, but Inadequate in Double/Triple Hit or Expressing DLBCL

Lori A. Leslie, MD, Sejal Kothadia, MD, Ewelina Protomastro, MS, Patricia J Greenberg, Tracy Andrews, PhD, Ann McNeill, ANP, Hoshiyuki Iida, Alan P Skarbnik, MD, Xiao Yang, Pritish K. Bhattacharyya, MD, Kar Fai Chow, MD, Stuart L. Goldberg, MD, Andrew L. Pecora, MD, Tatyana A Feldman, MD, Andre Goy, MD

Blood (2017) 130 (Supplement 1): 4163.

https://doi.org/10.1182/blood.V130.Suppl_1.4163.4163

Published: 2017

Journal Articles

Gene Expression Profiling (GEP) As a Prognostic Indicator of Multiple Myeloma, Irrespective of Disease Stage, Prior Treatment and Prior Transplant - a Single Center Experience

Miguel Gonzalez Velez, MD, Tracy Andrews, PhD, Narjust Duma, MD, Ning Dong, MD, Badal Thakkar, MD MPH, Giselle Suero, MD PhD, Joshua R Richter, MD, David H. Vesole, MD PhD, David Siegel, MD PhD, Noa Biran, MD

Blood (2017) 130 (Supplement 1): 3062.

https://doi.org/10.1182/blood.V130.Suppl_1.3062.3062

Published: 2017

Journal Articles

A Phase II Trial of the Anti -PD-1 Monoclonal Antibody Pembrolizumab (MK-3475) + Lenalidomide + Dexamethasone As Post Autologous Stem Cell Transplant Consolidation in Patients with High-Risk Multiple Myeloma

Noa Biran, MD, Tracy Andrews, PhD, Rena Feinman, PhD, David H. Vesole, MD PhD, Joshua R Richter, MD, Joshua Zenreich, Palka Anand, RN, BSN, CCRP, Laura McBride, RN, BSN, OCN, Kristin Ivanovski, RN, BSN, CCRP, Robert Korngold, PhD, David Siegel, MD PhD

Blood (2017) 130 (Supplement 1): 1831.

https://doi.org/10.1182/blood.V130.Suppl_1.1831.1831

Published: 2017

Journal Articles

Outcomes with Augmented Hyper-CVAD (AHCVAD), a Pediatric Inspired HCVAD-Based Regimen, for Adults Younger Than 50 Years of Age with Newly Diagnosed Acute Lymphoblastic Leukemia (ALL)

James K McCloskey, MD, Genique Stanislaus, ANP, Jamie L. Koprivnikar, MD, Tracy Andrews, PhD, Jones Elizabeth, Danielle Marcotulli, APN, Grace Perry, APN, Stuart L. Goldberg, MD, Stefan Faderl

Blood (2017) 130 (Supplement 1): 5050.

https://doi.org/10.1182/blood.V130.Suppl_1.5050.5050

Published: 2017

NARROW

Antibiotic Overload: Antibiotic Stewardship in Febrile Patients with Hematologic Malignancies

Cyclophosphamide Based Regimens Compared to Plerixafor-Based Regimens for Stem Cell Mobilization in Patients with Multiple Myeloma Result in Higher CD34+ Cell Yield, Lower Cost and Similar Outcome Post Autologous Transplantation

Risk of Engraftment Syndrome after Autologous Stem Cell Transplantation for Multiple Myeloma Increases with Age and Lower Dose of CD34+ Cells, but Is Not Impacted By Immunomodulatory Chemotherapy

Outcomes of Autologous Stem Cell Transplantation in Very Elderly Patients with Multiple Myeloma

Patients Responding to Any First Line Therapy for Multiple Myeloma Should Proceed to Autologous Stem Cell Transplantation Instead of Receiving Second Line Therapy to Deepen Response

Treatment of High Risk DLBCL with DA-R-EPOCH in Those Unable to Tolerate Intensive Chemotherapy: Well-Tolerated and Effective, but Inadequate in Double/Triple Hit or Expressing DLBCL

Gene Expression Profiling (GEP) As a Prognostic Indicator of Multiple Myeloma, Irrespective of Disease Stage, Prior Treatment and Prior Transplant - a Single Center Experience

A Phase II Trial of the Anti -PD-1 Monoclonal Antibody Pembrolizumab (MK-3475) + Lenalidomide + Dexamethasone As Post Autologous Stem Cell Transplant Consolidation in Patients with High-Risk Multiple Myeloma

Outcomes with Augmented Hyper-CVAD (AHCVAD), a Pediatric Inspired HCVAD-Based Regimen, for Adults Younger Than 50 Years of Age with Newly Diagnosed Acute Lymphoblastic Leukemia (ALL)

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only